Aptose Showcases Clinical And Preclinical Results For Tuspetinib (TUS) At The 2024 EHA Hybrid Congress

6/14/24 7:34:09 AM ET

$APTO

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $APTO alert in real time by email

TUS Monotherapy and TUS+Venetoclax (VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or refractory (R/R) Acute Myeloid Leukemia (AML) and Differentiate TUS from other Investigational Drugs in AML

TUS Monotherapy and TUS+VEN Doublet Therapy Active in Difficult-to-treat Genetic Subgroups, FLT3 Wildtype AML

TUS Shown to Target VEN Resistance Mechanisms and Retain Activity on VEN-Resistant AML Cells in Preclinical Study

TUS+VEN+Azacitidine (AZA) Triplet Trial to Treat Newly Diagnosed AML Patients; Clinical Sites Being Activated

Get the next $APTO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$APTO

Date	Price Target	Rating	Analyst
12/21/2021	$14.00 → $12.00	Buy	HC Wainwright & Co.
11/12/2021	$9.00 → $14.00	Buy	HC Wainwright & Co.

More analyst ratings

NodThera Announces Appointment of Greg Chow as Chief Financial and Business Officer
NodThera Announces Appointment of Greg Chow as Chief Financial and Business Officer Greg brings over 25 years of public and private company leadership experience Philadelphia, PA, August 1, 2024 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the appointment of Greg Chow as Chief Financial and Business Officer (CFBO), effective immediately. Greg is an experienced executive with over 25 years of corporate finance, capital markets, investment banking, financial accounting, drug development operations, and business development experience. Over th
8/1/24 7:00:00 AM ET
$APTO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Aptose Announces Results from Annual and Special Meeting of Shareholders
SAN DIEGO and TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the voting results from the Company's annual and special meeting of shareholders held today, June 18, 2024 (the "Meeting"). A total of 8,101,527 common shares of the Company, representing 49.67% of the common shares of the Company entitled to be voted, were represented by shareholders present or represented by proxy at the Meeting. The Company is pleased to announce that all of the nominees listed in the proxy
6/18/24 5:30:00 PM ET
$APTO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
SAN DIEGO and TORONTO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced the appointment of Fletcher Payne to Chief Business Officer, in addition to his role as Senior Vice President, Chief Financial Officer. With a healthcare tenure of more than 25 years, Mr. Payne has held several CFO and senior management positions at biotech companies in addition to finance and accounting roles, and has overseen legal, corporate development and licensing functions. During his career, he has execu
11/30/23 4:59:54 PM ET
$APTO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$APTO
Press Releases

Fastest customizable press release news feed in the world

Aptose Reports Results for the Third Quarter 2024
SAN DIEGO and TORONTO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for the three months ended September 30, 2024, and provided a corporate update. "Triple drug therapies (triplets) that build on the standard of care in AML have yielded higher response rates yet are limited to specific subpopulations and often cause myelosuppression and other toxicities," said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer of Aptose. "Tuspetinib, with
11/8/24 4:01:00 PM ET
$APTO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Aptose Announces Results from Special Meeting of Shareholders
SAN DIEGO and TORONTO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing tuspetinib, a highly differentiated oral kinase inhibitor for the treatment of patients with acute myeloid leukemia (AML), announced the voting results from its special meeting of shareholders held today, September 5, 2024 (the "Meeting"). A total of 6,052,460 common shares of the Company (the "Shares"), representing 33.42% of the issued and outstanding Shares were voted at the Meeting. The proposals put forward before the Company's shareholders for consideration and approval, as set out in the Company
9/5/24 4:15:00 PM ET
$APTO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
SAN DIEGO and TORONTO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing tuspetinib, a highly differentiated oral kinase inhibitor for the treatment of patients with acute myeloid leukemia (AML), today announced that it received a $10 million loan through a Facility Agreement with Hanmi Pharmaceutical Co. Ltd. ("Hanmi"). The loan is convertible as prepayment of milestone obligations under the Future Collaboration Agreement (as defined hereinafter) or repayable after the expected completion of a triple drug combination trial with tuspetinib in newly diagnosed AML patients. Apto
8/30/24 4:30:02 PM ET
$APTO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$APTO
Financials

Live finance-specific insights

Aptose Reports Results for the First Quarter 2024
TUS+VEN+HMA Triplet Protocol in 1L Therapy for Newly Diagnosed AML was Submitted to the FDA During Q1 and is Now Being Activated at Clinical Sites TUS+VEN+HMA Triplet 1L Therapy for Newly Diagnosed AML is Supported by Extensive TUS and TUS+VEN Data from Completed Trials with R/R AML Conference Call and Webcast at 5:00 pm ET Today SAN DIEGO and TORONTO, May 14, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for the first quarter ended March 31, 2024. The Company will p
5/14/24 4:01:00 PM ET
$APTO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024
SAN DIEGO and TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the first quarter ended March 31, 2024, on Tuesday, May 14, 2024, after the close of the market, and provide a corporate update. In addition, Rafael Bejar, MD, PhD, the Company's Chief Medical Officer and resident Key Opinion Leader, will review a selection of slides and discuss the clinical strategy for advancing the Company's lead asset tuspetinib (TUS) in a TUS+VEN+HMA triplet drug combination for the frontline treatmen
5/6/24 4:30:00 PM ET
$APTO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
SAN DIEGO and TORONTO, March 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the fourth quarter and year ended December 31, 2023, on Tuesday, March 26, 2024, after the close of the market, and provide a corporate update. Conference Call & Webcast: Date:Tuesday, March 26, 2024Time:5:00 PM ETAudio Webcast Only:linkQ&A Participant Registration Link*:link(https://register.vevent.com/register/BIe69f08fc83634a6aa38bf7081d82c6a2) *Analysts interested in participating in the question-and-answer sess
3/18/24 4:30:00 PM ET
$APTO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Aptose Showcases Clinical And Preclinical Results For Tuspetinib (TUS) At The 2024 EHA Hybrid Congress

Chat with this insight

Recent Analyst Ratings for $APTO

$APTO Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D/A filed by Aptose Biosciences Inc. (Amendment)

SEC Form SC 13G/A filed by Aptose Biosciences Inc. (Amendment)

SEC Form SC 13D filed by Aptose Biosciences Inc.

$APTO Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4: Seizinger Bernd R. bought $53,380 worth of shares (17,000 units at $3.14)

$APTO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Ledru Philippe

SEC Form 4 filed by Payne Fletcher

SEC Form 4 filed by Bejar Rafael

$APTO SEC Filings

Aptose Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Amendment: SEC Form S-1/A filed by Aptose Biosciences Inc.

Aptose Biosciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

$APTO Leadership Updates

Live Leadership Updates

$APTO Market Insights

Live Market Insights

NodThera Announces Appointment of Greg Chow as Chief Financial and Business Officer

Aptose Announces Results from Annual and Special Meeting of Shareholders

Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role

HC Wainwright & Co. Reiterates Buy on Aptose Biosciences, Maintains $7 Price Target

Aptose Showcases Clinical And Preclinical Results For Tuspetinib (TUS) At The 2024 EHA Hybrid Congress

Aptose Biosciences Shares Move Higher; Traders Circulate Zacks Article Titled "Aptose Biosciences Upgraded to Buy: What Does It Mean for the Stock?"

$APTO Press Releases

Fastest customizable press release news feed in the world

Aptose Reports Results for the Third Quarter 2024

Aptose Announces Results from Special Meeting of Shareholders

Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib

$APTO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

HC Wainwright & Co. reiterated coverage on Aptose Biosciences with a new price target

HC Wainwright & Co. reiterated coverage on Aptose Biosciences with a new price target

Oppenheimer reiterated coverage on Aptose Biosciences with a new price target

$APTO Financials

Live finance-specific insights

Aptose Reports Results for the First Quarter 2024

Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024

Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024

Recent Analyst Ratings for
$APTO

$APTO
Large Ownership Changes

$APTO
Insider Purchases

$APTO
Insider Trading

$APTO
SEC Filings

$APTO
Leadership Updates

$APTO
Market Insights

$APTO
Press Releases

$APTO
Analyst Ratings

$APTO
Financials